Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
BioNTech and Bristol Myers Squibb Form $11B Partnership for Cancer Drug Development.
Jun 02, 2025•about 1 year ago
Contract Type
partnership
Description
BioNTech SE and Bristol Myers Squibb have announced a partnership for the co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A. The collaboration aims to leverage both companies' expertise to advance this investigational drug across various solid tumor types.
Related People
Suggested for you
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months